Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15436463 | 0.91 | NPC1 (0.41) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL16472097 | 0.89 | PDE4B (0.42) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL15436555 | 0.86 | LMNA (0.41) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL15436455 | 0.84 | LMNA (0.45) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL23273674 | 0.83 | NPC1 (0.52) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL1198982 | 0.80 | NPC1 (0.49) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL13164488 | 0.79 | PDE4B (0.40) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL1198694 | 0.76 | NPC1 (0.49) | NPC1LMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL3265402 | 0.76 | SMN1; SMN2 (0.60) | NPC1LMNARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13126460 | 0.76 | PDE4B (0.43) | NPC1LMNARAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687515-A1 | METHOD FOR PRODUCING PYRAZOLECARBOXYLIC ACID DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140012013-A1 | METHOD FOR PRODUCING PYRAZOLE CARBOXYLIC ACID DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012013-A1 | METHOD FOR PRODUCING PYRAZOLE CARBOXYLIC ACID DERIVATIVE | HSD11B1, HSD11B2, HSD17B1 | NPC1 1755/4885LMNA 4329/4885RAB9A 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.